Navigation Links
UC Davis researchers develop computer model for testing heart-disease drugs
Date:8/31/2011

(SACRAMENTO, Calif.) UC Davis researchers have developed an accurate computer model to test the effects of medications for arrhythmia, or abnormal heart rhythm, before they are used in patients.

The new tool -- described in the Aug. 31 issue of the journal Science Translational Medicine -- will help scientists screen anti-arrhythmia medications early in the drug-development pipeline and eventually guide physicians in prescribing those interventions to patients who could benefit the most.

"Drug development for arrhythmia has failed because it is difficult to anticipate how drugs will alter the heart's intricate electrical behavior prior to clinical trials," said Clancy, an associate professor of pharmacology at UC Davis and senior author of the study. "We developed a novel approach to solve this problem -- a computational framework for making early predictions about the effects of medications on cardiac rhythms."

In the 1980s, the Cardiac Arrhythmia Suppression Trial (CAST) study came to an abrupt halt when scientists discovered that the arrhythmia medication flecainide, used to treat abnormally fast heart rhythms, more than tripled the risk of sudden cardiac death compared to placebo in patients with irregular heartbeats.

"No one ever knew exactly why this happened, and we used our model to find out," said Clancy. "CAST gave us the clinical starting point for our study."

To further prove the model's utility, Clancy and her team also used it to test lidocaine, an anti-arrhythmia medication with a strong safety profile and sufficient clinical outcomes data.

In conducting the study, Clancy, a biophysicist who specializes in using high-performance computing to understand diseases arising from abnormal excitability, started with existing models that simulate the behavior of heart cells during both normal heart rhythms and arrhythmia. She then devised mathematical formulas to describe the interactions of flecainide and lidocaine with their specific cellular targets -- tiny pores in cell membranes called ion channels that are the foundation for cardiac electrical activity. She and her team used these models in a simulation study to predict the effects of these drugs on cardiac rhythms in a 3-D virtual heart.

The results can be seen as videos showing that in the setting of extra heartbeats, flecainide causes arrhythmia, the condition it was developed to treat. Arrhythmia was not observed with lidocaine, confirming this drug is a safer alternative.

"An additional benefit of this model is that we could see exactly how flecainide causes arrhythmia," Clancy said.

The test showed that flecainide detaches from ion channels very slowly, causing it to build up in cells. This drug action led to a loss of heartbeats in some portions of the heart but not others - a condition that can set the stage for arrhythmia.

According to the study's lead author, Jonathan D. Moreno, a major benefit of the computer-based drug-testing approach is that it allows researchers to follow many processes simultaneously.

"We can test treatments under a range of conditions, including various heart rates, drug concentrations and arrhythmia triggers," said Moreno, who was a graduate student in Clancy's lab when the study was conducted. "It could even be used to mix and match drugs to create multidrug regimens."

To confirm the results, Clancy and her team treated rabbit hearts with the two drugs and found that the simulation correctly predicted the heart rates and concentrations at which the adverse effects were seen with the computer model.

The researchers hope their model will provide the foundation for a virtual drug-testing system that could streamline the current approach, which is limited to just a few drugs and biological processes at a time. Clancy also hopes her research will lead to quicker discoveries of new arrhythmia therapeutics.

"Millions of people each year are affected by cardiac arrhythmias that don't respond well to medications or that must be controlled with implantable defibrillators that can reduce quality of life," said Clancy. "Our model will hopefully speed the discovery of new options."


'/>"/>
Contact: Karen Finney
karen.finney@ucdmc.ucdavis.edu
916-734-9064
University of California - Davis Health System
Source:Eurekalert

Related medicine news :

1. UC Davis pain research may pave the way to understanding and controlling chronic pain
2. UC Davis surgeons test innovative device in patient with swallowing disorder
3. Inhaled steroids increase diabetes risk, say Lady Davis Institute researchers
4. UC Davis scientists find link between arthritis pain reliever and cardiovascular events
5. UC Davis study finds low liver cancer survival rates among Laotian/Hmong-Americans
6. New UC Davis study finds early Alzheimers identification method
7. DavisPTnetwork Recruits Bloggers to Report Key Session Learning Points Live from APTA 2010
8. DavisPTnetwork Partners with the Florida Physical Therapy Association to Provide Online Continuing Education
9. DavisPTnetwork Partners with the New York Physical Therapy Association to Provide Online Continuing Education
10. Stanford researchers invent sutureless method for joining blood vessels
11. Yale researchers use genetic code to engineer a living protein
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/21/2017)... ... 2017 , ... The Bryant Agency, a Georgia based firm ... in the Dalton region, is working in conjunction with the GreenHouse organization in ... abuse. , The GreenHouse is headquartered in Dalton and provides a refuge for ...
(Date:7/21/2017)... , ... July 21, 2017 , ... ... assistance and financial planning services to communities in the greater Birmingham area, is ... provide resources to underprivileged young people in the region. , The Chris Hammond ...
(Date:7/21/2017)... ... , ... Hospital M&A activity slowed in the second quarter of 2017, according ... to 23 in the second quarter, up 15% from the 20 publicly announced acquisitions ... in the year-ago second quarter. Only four of the transactions disclosed a purchase price ...
(Date:7/21/2017)... ... July 21, 2017 , ... The ... grant from the C. R. Bard Foundation, Inc. to support the ... , a service available through the nonprofit home care agency. Using evidence-based methods, ...
(Date:7/21/2017)... ... July 21, 2017 , ... West Dermatology is pleased to announce the ... July 17, 2017, Ms. Vu will join West Dermatology’s large network of medical and ... skin cancer , and more. She graduated from the University of Florida College ...
Breaking Medicine News(10 mins):
(Date:7/11/2017)... , July 11, 2017 Oramed Pharmaceuticals ... a clinical-stage pharmaceutical company focused on the development of ... Food and Drug Administration (FDA) has agreed to schedule ... completed Phase IIb trial of its oral insulin capsule ... Phase IIb trial met primary and secondary endpoints by ...
(Date:7/10/2017)... CARLSBAD, Calif. , July 10, 2017  The ... in Boston, MA at the ... unequaled value and unparalleled access to global decision makers ... to draw 800+ life science leaders during two impactful ... Boston, and provides delegates with additional networking opportunities with ...
(Date:7/5/2017)... JERUSALEM , July 5, 2017 ... www.oramed.com ), a clinical-stage pharmaceutical company ... today that it has received approval from the Israel Securities ... Stock Exchange (TASE). Oramed common stock will commence trading on ... Based on the current market capitalization of the Company, it ...
Breaking Medicine Technology: